Susan G. Kozauer, MD

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.